Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies.

Neily Zakiyah, Widya N Insani, Auliya A Suwantika, Jurjen van der Schans, Maarten J Postma
Author Information
  1. Neily Zakiyah: Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Padjadjaran University, Bandung 40132, Indonesia. ORCID
  2. Widya N Insani: Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Padjadjaran University, Bandung 40132, Indonesia. ORCID
  3. Auliya A Suwantika: Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Padjadjaran University, Bandung 40132, Indonesia. ORCID
  4. Jurjen van der Schans: Unit of Global Health, Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, The Netherlands.
  5. Maarten J Postma: Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Padjadjaran University, Bandung 40132, Indonesia.

Abstract

Evidence on costs and health benefits of pneumococcal conjugate vaccine (PCV) for children in Asian countries is limited but growing. As a region with a considerably high burden of pneumococcal disease, it is prominent to have a comprehensive overview on the cost-effectiveness of implementing and adopting a PCV vaccination program. We conducted a systematic review from Pubmed and Embase to identify economic evaluation studies of PCV for children in Asian countries up to May 2020. Data extraction included specific characteristics of the study, input parameters, cost elements, cost-effectiveness results, and key drivers of uncertainty. The Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement was followed for this systematic review. The reporting quality of the included studies was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. After the screening process on both the title and abstract and full text of 518 records, a total of 25 studies fulfilled the inclusion criteria, and were included in the review. The majority of included studies demonstrates that PCV for children is cost-effective in most of the Asian region, and even cost-saving in some countries. Most of the included studies implemented cost utility analysis (CUA) using either quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Overall, the main drivers affecting the cost effectiveness were vaccine price, burden regarding pneumonia-related parameters, and the inclusion of herd effects. The children pneumococcal vaccination program appears to be a cost-effective intervention in Asia, and even cost-saving in certain conditions. Vaccine price, pneumonia-related disease burden, and the inclusion of the herd effect are observed as important key drivers in estimating cost-effectiveness in this region. Incorporating PCV in vaccination programs in this region was found to be highly favorable.

Keywords

References

  1. Lancet Infect Dis. 2019 May;19(5):497-509 [PMID: 30975525]
  2. Clin Infect Dis. 2014 Oct 15;59(8):1066-73 [PMID: 25034421]
  3. Int J Technol Assess Health Care. 2010 Jul;26(3):330-3 [PMID: 20584363]
  4. BMC Infect Dis. 2015 Jul 24;15:284 [PMID: 26206275]
  5. Cost Eff Resour Alloc. 2017 Aug 22;15:17 [PMID: 28852326]
  6. Lancet. 2009 Sep 12;374(9693):893-902 [PMID: 19748398]
  7. Pharmacoeconomics. 2016 Dec;34(12):1211-1225 [PMID: 27510721]
  8. Expert Rev Anti Infect Ther. 2012 Jun;10(6):707-19 [PMID: 22734960]
  9. Hum Vaccin Immunother. 2016;12(2):403-16 [PMID: 26451658]
  10. Value Health Reg Issues. 2014 May;3:156-166 [PMID: 29702921]
  11. Expert Rev Vaccines. 2011 Jul;10(7):951-80 [PMID: 21806394]
  12. Value Health Reg Issues. 2013 May;2(1):64-74 [PMID: 29702855]
  13. Infect Drug Resist. 2014 Jan 10;7:15-24 [PMID: 24453496]
  14. Vaccine. 2013 Jun 10;31(26):2839-47 [PMID: 23588084]
  15. Vaccine. 2017 Feb 15;35(7):1055-1063 [PMID: 28109706]
  16. Vaccines (Basel). 2020 May 18;8(2): [PMID: 32443523]
  17. Value Health Reg Issues. 2014 May;3:146-155 [PMID: 29702920]
  18. J Formos Med Assoc. 2013 Mar;112(3):151-60 [PMID: 23473528]
  19. Lancet Glob Health. 2019 Jan;7(1):e58-e67 [PMID: 30554762]
  20. Value Health. 2012 Jan-Feb;15(1 Suppl):S15-9 [PMID: 22265061]
  21. JAMA. 1999 Oct 20;282(15):1453-7 [PMID: 10535436]
  22. Vaccine. 2018 Mar 20;36(13):1757-1765 [PMID: 29478752]
  23. Lancet Infect Dis. 2004 Mar;4(3):144-54 [PMID: 14998500]
  24. PLoS Med. 2009 Jul 21;6(7):e1000097 [PMID: 19621072]
  25. Vaccine. 2012 May 9;30(22):3320-8 [PMID: 22386745]
  26. BMC Health Serv Res. 2014 Feb 07;14:56 [PMID: 24507480]
  27. Hum Vaccin Immunother. 2017 Jul 3;13(7):1681-1687 [PMID: 28414567]
  28. Lancet. 2003 Aug 2;362(9381):355-61 [PMID: 12907008]
  29. J Glob Health. 2013 Jun;3(1):010401 [PMID: 23826505]
  30. Health Econ. 2010 May;19(5):518-31 [PMID: 19382106]
  31. J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45 [PMID: 20044845]
  32. Value Health. 2009 Nov-Dec;12 Suppl 3:S42-8 [PMID: 20586981]
  33. PLoS One. 2015 Jul 01;10(7):e0131156 [PMID: 26131961]
  34. Hum Vaccin Immunother. 2018 Jun 3;14(6):1444-1452 [PMID: 29425054]
  35. Pediatr Infect Dis J. 2016 Nov;35(11):e353-e361 [PMID: 27753771]
  36. Lancet Infect Dis. 2014 Mar;14(3):205-12 [PMID: 24287186]
  37. Value Health Reg Issues. 2013 Sep - Oct;2(2):259-263 [PMID: 29702874]
  38. Epidemiol Infect. 2005 Oct;133(5):891-8 [PMID: 16181510]
  39. Hum Vaccin Immunother. 2015;11(5):1081-7 [PMID: 25874476]
  40. Value Health. 2016 Dec;19(8):929-935 [PMID: 27987642]
  41. Pharmacoeconomics. 2008;26(3):191-215 [PMID: 18282015]
  42. Clin Infect Dis. 2017 Jun 15;64(suppl_3):S188-S196 [PMID: 28575369]
  43. Vaccine. 2019 Jan 21;37(4):623-630 [PMID: 30587430]
  44. Vaccine. 2009 Dec 9;27(52):7282-91 [PMID: 19393708]
  45. PLoS One. 2018 Jul 25;13(7):e0201245 [PMID: 30044865]
  46. BMC Infect Dis. 2013 May 04;13:202 [PMID: 23641904]
  47. Value Health Reg Issues. 2014 May;3:197-204 [PMID: 29702928]
  48. Value Health. 2013 Mar-Apr;16(2):231-50 [PMID: 23538175]
  49. Hum Vaccin Immunother. 2018 Jan 2;14(1):85-94 [PMID: 29115905]
  50. Vaccine. 2013 Jun 7;31(25):2762-71 [PMID: 23588088]
  51. Vaccine. 2016 Dec 7;34(50):6343-6349 [PMID: 27810315]
  52. Clin Microbiol Rev. 2012 Jul;25(3):409-19 [PMID: 22763632]
  53. Pediatr Infect Dis J. 2003 Jan;22(1):10-6 [PMID: 12544402]
  54. Vaccine. 2016 May 17;34(23):2622-6 [PMID: 27026150]
  55. N Engl J Med. 2011 Nov 10;365(19):1760-1 [PMID: 22010866]
  56. Infect Dis Ther. 2014 Dec 20;: [PMID: 25527448]
  57. Expert Rev Vaccines. 2015 Apr;14(4):589-604 [PMID: 25482311]
  58. BMJ. 2010 Jun 02;340:c2509 [PMID: 20519267]

Grants

  1. 1733/UN6.3.1/LT/2020/Universitas Padjadjaran

Word Cloud

Created with Highcharts 10.0.0PCVchildrenstudiesincludedpneumococcalAsianregioncost-effectivenesscostvaccinecountriesburdenvaccinationreviewdriversinclusionconjugatediseaseprogramsystematicparameterskeyReportingSystematicstatementusingEconomicEvaluationcost-effectiveevencost-savinganalysislifeyearspricepneumonia-relatedherdAsiaEvidencecostshealthbenefitslimitedgrowingconsiderablyhighprominentcomprehensiveoverviewimplementingadoptingconductedPubmedEmbaseidentifyeconomicevaluationMay2020DataextractionspecificcharacteristicsstudyinputelementsresultsuncertaintyPreferredItemsReviewsMetaAnalysesPRISMAfollowedreportingqualityevaluatedConsolidatedHealthStandardsCHEERSscreeningprocesstitleabstractfulltext518recordstotal25fulfilledcriteriamajoritydemonstratesimplementedutilityCUAeitherquality-adjustedQALYsdisability-adjustedDALYsOverallmainaffectingeffectivenessregardingeffectsappearsinterventioncertainconditionsVaccineeffectobservedimportantestimatingIncorporatingprogramsfoundhighlyfavorablePneumococcalVaccinationChildrenCountries:ReviewStudies

Similar Articles

Cited By